How blood tests can inform cancer treatment decisions, with Craig Eagle

Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer prognosis and treatment prediction.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Craig Eagle, Chief Medical Officer of Guardant Health, a precision medicine company that offers blood tests to inform cancer treatment decisions.

Eagle discusses Guardant’s participation in the National Cancer Institute’s Vanguard Study, as well as screening, recurrence monitoring, and therapy selection focused on conquering cancer with data, with examples especially in the colorectal cancer space.

You can listen to episode 229 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.